Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Hyung L. Kim, Eddie Mayerson, Primo N Lara, Edward Messing, Cathy Tangen, Brian M. Shuch, Ulka Vaishampayan

Research output: Contribution to journalComment/debate

4 Scopus citations

Abstract

Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StatePublished - Jan 1 2019

Keywords

  • cytoreductive nephrectomy
  • immunotherapy
  • metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

  • Cite this